Jéssica Ruivo Maximino

ORCID: 0000-0002-3955-206X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Amyotrophic Lateral Sclerosis Research
  • Neurogenetic and Muscular Disorders Research
  • Neurological diseases and metabolism
  • Neurogenesis and neuroplasticity mechanisms
  • Muscle Physiology and Disorders
  • Neuropeptides and Animal Physiology
  • Pain Mechanisms and Treatments
  • Lymphoma Diagnosis and Treatment
  • Genetic Neurodegenerative Diseases
  • Receptor Mechanisms and Signaling
  • Stress Responses and Cortisol
  • Nerve injury and regeneration
  • Exercise and Physiological Responses
  • Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Pediatric Pain Management Techniques
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Neuroscience of respiration and sleep
  • MicroRNA in disease regulation
  • Circadian rhythm and melatonin
  • Alzheimer's disease research and treatments
  • Regulation of Appetite and Obesity
  • Axon Guidance and Neuronal Signaling
  • Thermal Regulation in Medicine
  • Transcranial Magnetic Stimulation Studies
  • Muscle activation and electromyography studies

Universidade de São Paulo
2006-2024

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2014-2024

National Council for Scientific and Technological Development
2015-2016

Christie's
2016

Fundação de Amparo à Pesquisa do Estado de São Paulo
2016

Universidade Federal de São Paulo
2015

Directorate-General for Interpretation
2015

Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disorder affecting motoneurons and the SOD1G93A transgenic mice are widely employed to study disease physiopathology therapeutic strategies. Despite cellular biochemical evidences of an early motor system dysfunction, conventional behavioral tests do not detect impairments in SOD1 mouse model. We evaluated changes behavior ALS by doing analyses tail elevation, footprint, automatic recording activities means infrared motion...

10.1016/j.brainres.2011.02.060 article EN publisher-specific-oa Brain Research 2011-02-26

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease that leads to widespread motor neuron death, general palsy and respiratory failure. The most prevalent sporadic ALS form not genetically inherited. Attempts translate therapeutic strategies have failed because the described mechanisms of are based on animal models carrying specific gene mutations thus do address ALS. In order achieve better approach study human disease, induced pluripotent stem cell...

10.3389/fncel.2015.00289 article EN cc-by Frontiers in Cellular Neuroscience 2015-08-04

Objective: To investigate gene mutations in familial form (FALS) and sporadic (SALS) of amyotrophic lateral sclerosis (ALS) a highly miscegenated population. Methods: Frequencies the C9orfF72, TARDBP, SOD1, FUS VAPB genes were investigated cohort FALS (n = 39) SALS 189) subjects from Research Centre University São Paulo School Medicine. All patients subjected to C9orf72 TARDBP analyses. also evaluated subjects. Results: Mutations identified (61.3%) (5.3%) patients. (12.8%, >45 GGGGCC...

10.1080/21678421.2016.1254245 article EN Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2016-12-15

Early molecular events related to cytoskeleton are poorly described in Amyotrophic Lateral Sclerosis (ALS), especially the Schwann cell (SC), which offers strong trophic support motor neurons. Database for Annotation, Visualization and Integrated Discovery (DAVID) tool identified cytoskeleton-related genes by employing Cellular Component Ontology (CCO) a large gene profiling of lumbar spinal cord sciatic nerve presymptomatic SOD1(G93A) mice. One five CCO terms were from deregulated 40 days...

10.3389/fncel.2014.00148 article EN cc-by Frontiers in Cellular Neuroscience 2014-05-26

Corticosteroids cause muscle atrophy by acting on proteasomal and lysosomal systems affecting pathways related to muscular trophysm, such as the IGF-1/PI-3k/Akt/mTOR. Omega-3 fatty acid (n-3) has been used beneficially attenuate linked sepsis cachexia; however, its effect dexamethasone-induced not evaluated. Objectives . We evaluated whether n-3 supplementation could mitigate development of atrophy. Methods Two groups Wistar rats were orally supplemented with or vehicle solution for 40 days....

10.1155/2014/961438 article EN cc-by BioMed Research International 2014-01-01

Background: Mutations in GRN (progranulin) and MAPT (microtubule-associated protein tau) are among the most frequent causes of monogenic frontotemporal dementia (FTD), but data on frequency these mutations regions such as Latin America still lacking. Objective: We aimed to investigate frequencies FTD cohorts from 2 Brazilian research centers, University Sao Paulo Federal Minas Gerais medical schools. Methods: included 76 probands diagnosed with behavioral-variant (n=55), semantic-variant...

10.1097/wad.0000000000000153 article EN Alzheimer Disease & Associated Disorders 2016-04-29

PURPOSE: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that displays rapid evolution. Current treatments have failed to revert clinical symptoms because the mechanisms involved in death of motoneuron are still unknown. Recent publications put non-neuronal cells, particularly, astrocyte and microglia, scenario pathophisiology disease. Animal models for ALS, particularly transgenic mice expressing human SOD1 gene with G93A mutation (hSOD1), available display...

10.1590/s0102-86502010000300011 article EN cc-by Acta Cirúrgica Brasileira 2010-05-19

Objective The aim of this study was to investigate the functional responses and plastic cortical changes in a sample animals with sequelae cerebral ischemia that were subjected model electrical stimulation (FES). Design Rats received an ischemic lesion (Rose Bengal method) randomized submitted FES (1–2 mA, 30 Hz, 20–40 mins for 14 days) or sham stimulation. Foot Fault Test performed before inducing also after FES. Brain immunochemistry labeling microtubule-associated protein–2...

10.1097/phm.0000000000000104 article EN American Journal of Physical Medicine & Rehabilitation 2014-05-06

Patients with sarcoglycanopathies, which comprise four subtypes of autosomal recessive limb-girdle muscular dystrophies, usually present progressive weakness leading to early loss ambulation and premature death, no effective treatment is currently available. Objective To clinical aspects outcomes six children sarcoglycanopathies treated steroids for at least one year. Method Patient files were retrospectively analyzed steroid use. Results Stabilization muscle strength was noted in patient, a...

10.1590/0004-282x20140126 article EN cc-by-nc Arquivos de Neuro-Psiquiatria 2014-10-01

Pigment epithelium derived factor (PEDF) exerts trophic actions to motoneurons and modulates nonneuronal restorative events, but its effects on neuroplasticity responses after spinal cord (SC) injury are unknown. Rats received a low thoracic SC photothrombotic ischemia local injection of PEDF were evaluated behaviorally six weeks later. detailed in ventral horn (motor) the levels lumbar central pattern generator (CPG), far from site. Molecules related (MAP-2), those that able modulate such...

10.1155/2014/451639 article EN cc-by Neural Plasticity 2014-01-01

Schwann cells are the main source of paracrine support to motor neurons. Oxidative stress and mitochondrial dysfunction have been correlated neuron death in Amyotrophic Lateral Sclerosis (ALS). Despite involvement early neuromuscular disruption ALS, detailed molecular events a dying-back triggering unknown. Sciatic nerves presymptomatic (60-day-old) SOD1(G93A) mice were submitted high-density oligonucleotide microarray analysis. DAVID demonstrated deregulated genes related death,...

10.3389/fncel.2015.00332 article EN cc-by Frontiers in Cellular Neuroscience 2015-09-01

To evaluate the effect of 2% lidocaine, 0.5% bupivacaine, and 0.75% ropivacaine on release substance P (SP) calcitonin gene-related peptide (CGRP) in skin wounds.A primary, experimental, analytical, prospective, self-controlled, blinded study.The study is set a university research center.Twenty-eight Wistar rats were randomly divided into 4 groups: ropivacaine, control. After general anesthesia, local anesthetic or 0.9% saline (control) was injected subdermally along 2-cm line dorsal midline...

10.1097/01.asw.0000480096.01724.91 article EN Advances in Skin & Wound Care 2016-03-19

To investigate the subcutaneous injection of carbon dioxide (CO2) on neuropeptides Calcitonin Gene-Related Peptide (CGRP) and Substance P (SP) secretion in rat skin.Fifty-six Wistar-EPM rats were distributed two groups: one for CGRP analysis, other SP analysis. Each group was subdivided into four subgroups: control (Cont), with needle (ContNd), CO2 (CO2Inj) atmospheric air (AirInj) - seven animals each. Sample analyses partial skin conducted by Western Blotting (WB).In group, there a...

10.1590/s0102-86502014000400002 article EN cc-by Acta Cirúrgica Brasileira 2014-04-01

PURPOSE: To investigate the neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) after subcutaneous injection of dexamethasone prior to skin incision in rats. METHODS: Twenty seven Wistar-EPM-1 rats were randomly divided into three groups. The sham group (SG) was injected with 0.9 % saline. second (Dexa) 1.0 mg/kg dexamethasone, third (Dexa+) 10.0 dexamethasone. In all groups, injections performed 30 minutes surgical tissue collection. SP CGRP (15 kDa pro-CGRP 5 CGRP)...

10.1590/s0102-865020150080000002 article EN cc-by Acta Cirúrgica Brasileira 2015-08-01

To describe and standardize a protocol that overcomes the technical limitations of Western blot (WB) analysis in quantification neuropeptides substance P (SP) calcitonin gene-related peptide (CGRP) following nociceptive stimuli rat skin.Male Wistar rats (Rattus norvegicus albinus) weighing 250 to 350 g were used this study. Elements WB adapted by using specific manipulation samples, repeated cycles freezing thawing, more thorough maceration, potent homogenizer; increasing lytic reagents;...

10.1097/01.asw.0000465373.42350.c1 article EN Advances in Skin & Wound Care 2015-05-19
Coming Soon ...